How bacteria fight back against promising antimicrobial peptide
Antimicrobial peptides have potential in antibiotic drug development, including possible uses in combination with other antibiotics for infections that are difficult to treat. Scientists have shown that the peptide TAT-RasGAP317-326, originally developed as an anticancer compound, inhibits E. coli and Staphylococcus aureus, among other bacteria. The peptide contains residues 317-326 of the Ras GTPase-activating protein, or RasGAP, with an attached N-terminal cell-penetrating sequence from the HIV transactivator of transcription, or TAT, protein, and will be called TAT-RasGAP in this article for simplicity. Maria Georgieva at the University of Lausanne Hospital Center and a team in Switzerland performed a resistance selection experiment over 20 passages to obtain an E. coli strain resistant to TAT-RasGAP to identify mutations that could elucidate this peptide’s mechanism of action. In a recent Journal of Biological Chemistry article, they showed that a mutation in BamA, an outer membrane protein critical for the insertion of other membrane proteins, helped block the peptide’s antimicrobial activity.

The authors traced the mutation that protects E. coli from TAT-RasGAP to a negatively charged loop in BamA that extends into the extracellular space. The mutation changes a residue from a negative to a neutral charge. The authors hypothesized that the positively charged TAT-RasGAP may interact with this negatively charged loop for cell entry, and a negative-to-neutral mutation could have developed in the resistant strain to block this electrostatic interaction. Modeling and molecular dynamics indicated that BamA’s negatively charged loop likely interacts with the peptide.
However, further experiments showed that TAT-RasGAP does not produce the same changes as known BamA inhibitors based on bacterial morphology viewed by brightfield microscopy and outer membrane protein quantification, indicating that BamA is unlikely inhibited by TAT-RasGAP. Future experiments will help resolve the full mechanism of action for TAT-RasGAP and could lead to novel antibiotics.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

How signals shape DNA via gene regulation
A new chromatin isolation technique reveals how signaling pathways reshape DNA-bound proteins, offering insight into potential targets for precision therapies. Read more about this recent MCP paper.

A game changer in cancer kinase target profiling
A new phosphonate-tagging method improves kinase inhibitor profiling, revealing off-target effects and paving the way for safer, more precise cancer therapies tailored to individual patients. Read more about this recent MCP paper.

How scientists identified a new neuromuscular disease
NIH researchers discover Morimoto–Ryu–Malicdan syndrome, after finding shared symptoms and RFC4 gene variants in nine patients, offering hope for faster diagnosis and future treatments.

Unraveling cancer’s spaghetti proteins
MOSAIC scholar Katie Dunleavy investigates how Aurora kinase A shields oncogene c-MYC from degradation, using cutting-edge techniques to uncover new strategies targeting “undruggable” molecules.

How HCMV hijacks host cells — and beyond
Ileana Cristea, an ASBMB Breakthroughs webinar speaker, presented her research on how viruses reprogram cell structure and metabolism to enhance infection and how these mechanisms might link viral infections to cancer and other diseases.

Understanding the lipid link to gene expression in the nucleus
Ray Blind, an ASBMB Breakthroughs speaker, presented his research on how lipids and sugars in the cell nucleus are involved in signaling and gene expression and how these pathways could be targeted to identify therapeutics for diseases like cancer.